Novo Nordisk A/S has announced the initiation of the REDEFINE 11 trial, part of its ongoing REDEFINE clinical program, to further evaluate the efficacy and safety of CagriSema. The first patient visit for REDEFINE 11 occurred in early June 2025. This trial aims to explore the weight loss potential and safety of CagriSema 2.4 mg / 2.4 mg over a longer duration and with different protocol changes compared to previous trials. Results from the REDEFINE 1 trial, which demonstrated a 22.7% mean weight reduction in adults with overweight or obesity, have already been presented at the 85th Scientific Sessions of the American Diabetes Association and published in The New England Journal of Medicine. The clinical program will continue to assess the potential of CagriSema in upcoming trials.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.